Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study
- PDF / 630,167 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 53 Downloads / 139 Views
SHORT COMMUNICATION
Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study Sirio Fiorino1 · Michela Visani2,7 · Michele Masetti3 · Giorgia Acquaviva2 · Giovanni Tallini2 · Antonio De Leo2 · Adele Fornelli4 · Moira Ragazzi5 · Francesco Vasuri6 · Daniela Grifoni7 · Chiara Maria Argento7 · Thais Maloberti7 · Matteo Ravaioli8 · Carlo Fabbri9 · Elio Jovine3 · Annalisa Pession7 · Dario de Biase7 Received: 10 May 2020 / Accepted: 28 August 2020 © Springer Nature B.V. 2020
Abstract Pancreatic adenocarcinoma (PDAC) is the most frequent histological type of malignancy in the pancreas. Extracellular matrix (ECM), plays a critical role during the process of human carcinogenesis and the possible diversity in matricellular proteins composition of ECM may have a significant impact on the clinical course of PDAC. Aim of this paper was to evaluate the expression of three matricellular proteins, including Periostin (POSTN), Tenascin (TNS) and Osteopontin (OPN), in PDAC from long-survival (LS) and non-long survival (NLS) patients. A total of 30 PDAC were analyzed, 15 from patients that survived more than 60 months after surgery (LS) and 15 that died from the disease within 24 (NLS). RNA was extracted and OPN, TNS and POSTN mRNA levels were evaluated by qRT-PCR. LS and NLS samples showed the same type of POSTN and TN isoforms. On the contrary, OPN seems to be preferentially expressed in NLS PDAC. Moreover, OPNb and OPNc isoforms were expressed exclusively in NLS samples. In conclusion, Our data led to hypothesize a possible relationship between the expression of different isoforms of each of these proteins and the clinical outcome of patients with PDAC. Keywords Matricellular proteins · Gene expression · mRNA · Pancreatic adenocarcinoma · Cancer · Survival
Introduction Sirio Fiorino, Michela Visani shares co-authorship. Annalisa Pession, Dario de Biase shares senior authorship. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11033-020-05763-2) contains supplementary material, which is available to authorized users.
Pancreatic adenocarcinoma (PDAC) is the most frequent histological type of malignancy in the pancreas, accounting for near 90% of neoplasms in this organ [1]. It is one of the most aggressive human tumors, with a very dismal prognosis and an overall 5-years survival rate less than 5% [2]. In the last
* Sirio Fiorino [email protected]
5
Anatomic Pathology Unit, Arcispedale Santa Maria Nuova— IRCCS, Reggio Emilia, Italy
* Dario de Biase [email protected]
6
Anatomic Pathology Unit, “F. Addarii” Institute of Oncology and Transplantation Pathology, S. Orsola-Malpighi University Hospital, Bologna, Italy
7
Department of Pharmacy and Biotechnology, Dipartimento di Farmacia e Biotecnologie)—Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Viale Ercolani 4/2, 40139 Bologna, Italy
8
Department of General Surgery and Transplantation, St. Orsola-Malpighi
Data Loading...
